anti-EpCAM bispecific T-cell engager-secreting anti-HER2 CAR T-cell therapy (Fate Therapeutics)

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug Nameanti-EpCAM bispecific T-cell engager-secreting anti-HER2 CAR T-cell therapy (Fate Therapeutics)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein +[4]

Mechanisms of ActionEpithelial cell adhesion molecule modulatorsReceptor protein-tyrosine kinase erbB-2 modulators

TargetsEpithelial cell adhesion moleculeReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesFate Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesFate Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A